http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The Change of Gastric Antral Mucin Expression after Helicobacter pylori Irradication
마명신 ( Myung Sin Ma ),이길홍 ( Kil Hong Lee ),최정기 ( Jeong Ki Choi ),이승옥 ( Seung Ok Lee ),이수택 ( Soo Teik Lee ),강명재 ( Myoung Jae Kang ),김대곤 ( Dae Ghon Kim ),안득수 ( Deuk Soo Ahn ) 대한소화기학회 2002 대한소화기학회 춘계학술대회 Vol.2002 No.-
<Background and Aims> Helicobacter pylori colonizes the gastric surface epithelium, mucus glands and the mucus gel layer, It has been known that H. pylori infection causes aberrant gastric mucin expression. The aim of this study was to determine the effec
이길홍 ( Kil Hong Lee ),마명신 ( Myung Sin Ma ),이승옥 ( Seung Ok Lee ),이정민 ( Jeong Min Lee ),이수택 ( Soo Teik Lee ),김대곤 ( Dae Ghon Kim ),안득수 ( Deuk Soo Ahn ) 대한소화기학회 2002 대한소화기학회 춘계학술대회 Vol.2002 No.-
<Background/Aims> To describe the treatment efficacy and safety of radiofrequency ablation (RFA) to treat hepatocellular carcinoma (HCC) and metastatic liver tumors. Most patients with HCC are not candidates for resection because of multifocality, advance
증예(症例) : 혈관육종의 전이로 인한 상부 위장관 출혈 1예
남상우 ( Sang Woo Nam ),윤현정 ( Hyun Jung Yoon ),김성훈 ( Seong Hun Kim ),김상균 ( Sang Kyoon Kim ),민경훈 ( Kyung Hoon Min ),이호경 ( Ho Kyung Lee ),이나리 ( Na Ri Lee ),마명신 ( Myung Sin Ma ),이승옥 ( Seung Ok Lee ),김대곤 ( D 전북대학교 의과학연구소 2003 全北醫大論文集 Vol.27 No.1
Angiosarcoma is a rare malignant tumor which accounts for 1% to 2% of all soft tissue sarcomas. A 47-year-old man was presented to our emergency room because of general weakness and melena for 3 days. He had received a surgery for angiosarcoma of the aorta one year ago. Six months before the admission, angiosarcoma recurred at the anastomosis of site of the aorta, and metastatic lesions were found in the lung, pleura and skin of the buttock. Gastric fiberoscopy revealed two peanut sized, protuberant masses with ongoing bleeding at the body of the stomach and duodenum. Hemostatic procedure was performed immediately by a snare. No more active bleeding was noted and the patient was no report of upper gastrointestinal bleeding due to angiosarcoma in Korea, and we are hearby reporting with review of literature.
만성 B 형 간염 환자와 B 형 간염에 의한 간경변 환자에서의 Lamivudine 1 년 치료 효과
김승수,이승옥,안득수,김대곤,이수택,김용성,진흥용,마명신 대한간학회 2001 Clinical and Molecular Hepatology(대한간학회지) Vol.7 No.2
Background/Aims: Lamivudine is highly effective in suppressing hepatitis B virus replication and hepatitis B induced necroinflammatory activity. The objective of this study was to evaluate the virological and biochemical responses to lamivudine by patients with HBV associated chronic liver disease. In particular we stressed the importance of lamivudine therapy by patients with decompensated liver cirrhosis. Methods - We conducted a one - year trial of lamivudine in 80 patients with HBV associated chronic liver disease (chronic hepatitis 44, cirrhosis 36). We classified these patients according to the severity of hepatic dysfunction as chronic B hepatitis (Group A) or liver cirrhosis (Group B). These patients were treated for 12 months with 100 mg daily doses of lamivudine. Results: The seroconversion rate of HBeAg was 23.5% in group A patients and 26.7% in group B patients. The negative conversion of HBV - DNA was sustained for one year in 79.5% of patients in group A and 86.1% in group B. The normalization rates of serum ALT were 90.99% in group A and 88.9% in group B patients. No serious side effect after discontinuance of the treatment was found. There were 12 ALT breakthrough cases and all of them showed mutation of YMDD motif. However, they did not deteriorate clinically in spite of ALT elevation and HBV - DNA reappearance. The Child - Pugh scores improved even in patients with decompensated liver cirrhosis. Conclusion: One - year lamivudine treatment resulted in excellent virological and biochemical improvements and was well tolerated in the patients with HBV associated chronic liver disease, even in decompensated cirrhosis. We conclude that lamivudine is relatively safe in chronic hepatitis B and liver cirrhosis treatment..(Korean J Hepatol 2001;7:171-180)